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Abstrael Anaemia of chronic disease (ACD) is a com- 
mon extra-articular manifestation of rheumatoid 
arthritis (RA). Tumour necrosis factor alpha (TNFe) 
plays an important role in the development ofACD. The 
objective of the present study was to assess inhibition of 
in vitro colony-forming unit erythrocyte (CFUe) and 
blast-forming unit erythrocyte (BFUe) growth by TNFc~ 
and to examine whether this suppression could be coun- 
teracted by adding increasing concentrations of recombi- 
nant human erythropoietin (EPO) (r-h-EPO) to bone 
marrow cultures of RA patients with ACD and without 
anaemia (controls). Bone marrow cells of RA patients 
with ACD and control patients were cultured. The cul- 
tures were incubated with increasing concentrations of
r-h-EPO (0.25; 0.5; 1; 2 U/ml), each in combination with 
increasing quantities of TFNc~ (0; 50; 100; 200; 400 U/ 
ml). CFUe and BFUe were assessed after 7 and 14 days, 
respectively. Dose-dependent inhibition of BFUe and 
CFUe by increasing concentrations of TNFc~ was ob- 
served in ACD and controls. Regarding CFUe (ACD 
patients) incubated with 0.25 U/ml EPO, 50 U/ml TNFc~ 
caused 28% suppression compared to cultures without 
TNFc~. Increasing the concentration of r-h-EPO from 
0.25 U/ml to 2 U/ml completely restored the number of 
CFUe. A similar pattern was observed in BFUe growth 
in both groups. These data demonstrated the suppressive 
effects of TNFc~ on erythropoiesis in vitro and that the 
suppressed erythropoiesis could be partly corrected by 
the addition of excess r-h-EPO to the cultures. No signif- 
icant differences were observed between ACD and con- 
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trol RA patients. This in vitro model may help explain the 
clinical response to r-h-EPO therapy as documented in
RA patients with ACD. 
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Introduction 
Anaemia of chronic disease (ACD) is a common extra-ar- 
ticular manifestation ofactive rheumatoid arthritis (RA). 
Cytokines uch as interleukin 1beta (IL-113) and tumour 
necrosis factor alpha (TNFe) are immunoregulatory fac- 
tors and may be involved in the pathogenesis of rheumat- 
ic diseases and ACD [1-4]. ACD is associated with in- 
flammatory conditions associated with macrophage acti- 
vation. Activated macrophages produce a number of cy- 
tokines including IL-1, TNF~, interferon alpha and gam- 
ma (IFNa, IFNT), which may have an affect on erythro- 
poiesis [5, 6], thereby participating in the development of
ACD. Previous in vitro studies have shown the inhibition 
of CFUe and BFUe by TNF~ [7-11]. Whether these 
effects of TNF~ on erythroid progenitors are direct [8] or 
whether the presence of other cells is required [10, 11] is 
not entirely clear. In addition, chronic TNF~ exposure 
has been shown to suppress erythropoiesis in vivo [12, 
13]. Nude mice inoculated with Chinese hamster ovary 
(CHO) cells expressing the human TNFe gene developed 
a hypoferraemic, hypoproliferative anaemia with normal 
iron stores and decreased numbers of bone marrow and 
splenic CFUe and BFUe. These data suggest that chronic 
TNFc~ exposure in vivo may be involved in the develop- 
ment of ACD. Serum TNFc~ concentration has been 
shown to be elevated in RA patients with ACD and cor- 
relates well with RA disease parameters [14]. Based on 
the inverse correlation of serum TNFe and haemoglobin 
in the above-mentioned study [14] and in a group of HIV 
patients [15], it may be argued that TNFc~ plays a specific 
role in ACD. 
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Low plasma erythropoietin (EPO) levels in relation to 
the degree of anaemia in patients with acute or chronic 
tion, inflammation or malignancy despite a normal renal 
function [16-20]. Therefore, it is postulated that ACD 
patients are characterised by a relatively low EPO pro- 
duction. Decreased EPO sensitivity progenitors i postu- 
lated in RA and ACD [19]. ACD can be corrected with 
recombinant human EPO (r-h-EPO) therapy in patients 
with RA [20-25]. It has already been demonstrated that 
anaemia in mice caused exclusively by chronic TNF ex- 
posure can be corrected by administration of exogenous 
EPO [25]. Therefore, one may postulate that the benefi- 
cial effects of EPO on ACD in RA patients can be ex- 
plained, at least to some extent, by the ability of EPO to 
conteract TNF-mediated suppression of erythropoiesis. 
Therefore, we studied whether the suppressive effects of 
TNFe on erythropoiesis in vitro could be corrected with 
increasing r-h-EPO concentrations. We were also inter- 
ested in possible differences between TNFe-inhibited 
CFUe and BFUe colony growth and whether these ef- 
fects would differ between RA patients with ACD and 
RA patients without anaemia. 
was a indicated in the figures. R-h-EPO (Boehringer, Mannheim) 
was used as shown in Fig. 1. 
Colony culture assay 
Progenitor cells (0.5-1 x 105 cells/ml) of eight ACD patients and 
eight control patients were cultured in a mixture of Iscove's modi- 
fied Dulbecco's medium (IMDM), 1.1% methylcellulose, 30% fetal 
calf serum (FCS), bovine serum albumin (BSA), transferrin, 
lecithin, sodium selenite and 2-mercaptoethanol in a humidified 
atmosphere of 5% CO 2 in air at 37 ~ as reported previously [25]. 
Increasing concentrations of r-h-EPO (0.25; 0.5; 1; 2 U/ml), each in 
combination with increasing concentrations of TNF~ (0; 50; 100; 
200; 400 U/ml) were added to the cultures. CFUe and BFUe were 
scored after 7 and 14 days, respectively. 
Statistics 
The Wilcoxon signed-rank test was used to calculate statistical dif- 
ferences between the number of CFUe or BFUe under different 
conditions of incubation within one group. To established iffer- 
ences in CFUe or BFUe between the two groups, the two-sample 
Wilcoxon rank sum test was used. 
Patients and methods 
Preparation of cell suspension 
Bone marrow (BM) of eight RA patients with ACD (group 1) and 
eight RA patients without anaemia (control patients; group 2) was 
aspirated from the posterior iliac crest after the patients had given 
informed consent. The marrow was collected in Hank's balanced 
solution (HBBS) with heparin, diluted in HBBS, and mononuclear 
ceils were separated over Ficoll-Isopaque (1.077 g/cm2; Nycomed, 
Oslo, Norway). 
Recombinant human cytokines 
Recombinant human TNFe (1 U/ml is 16 pg/ml) was provided by 
Boehringer Institute (Vienna, Austria). The concentration of TNFe 
Results 
Inhibition of erythropoiesis by TNFc~ in vitro 
TNFe suppressed CFUe and BFUe growth in a dose- 
dependent manner (Tables I and 2; Fig. 1). The same 
inhibition occurred in both groups. 
Effect of r-h-EPO and CFUe and BFUe 
After the addition of increasing concentrations of r-h- 
EPO (0.25 U/ml up to 2 U/ml) the number of CFUe and 
BFUe increased in a dose-dependent manner. In cultures 
Table 1 Effect of erythropoietin (EPO) and tumour necrosis factor alpha (TNFa) on colony forming unit erythrocyte growth. Bone marrow 
of eight anaemia of chronic disease (ACD) patients and eight controls was incubated with increasing concentrations of EPO each in 
combination with increasing concentrations of TNFa. The median number of colonies and the range is shown 
TNF U/ml EPO U/m1 
0..25 0.5 1.0 2.0 
ACD Controls ACD Controls ACD Controls ACD Controls 
0 257 241 295 * 211 302 * 293 * 327 * 313 * 
(32-455) (42-425) (10-508) (22-590) (25-522) (30-525) (10-500) (30-867) 
50 209"* 206"* 284" 240 285' 289" 293" 333" 
(I5-290) (12-386) (15-681) (t5-475) (7-543) (15-400) (15-538) (35-502) 
100 183 ** I96 ** 222 *~ ** 222 *'** 286 * 275 * 286 * 273 * 
(7-297) (7-290) (0-451) (35-475) (2-544) (32-350) (2-370) (32-347) 
200 157"* 114"* 247" ** I98 * 256" 226 * 272"** 238 
(5-235) (17-305) (2-392) (15-280) (7-362) (45-275) (10-399) (32-322) 
400 127"* 140"* 216"** 168"** 238" 212" 237"** 222" 
(2-269) (10-t95) (5-265) (15-280) (5-297) (25-387) (0-361) (35-322) 
* P < 0.05 (compared to basic culture where 0.25 U/ml EPO was added without change in TNFa concentration) 
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Fig. 1 Effects of varying 
C 
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recombinant human erythropoietin 
(r-h-EPO) concentrations on inhibition of marrow cell colony form- 
ing units erythrocyte (CFUe) and blast forming unit erythrocyte 
(BFUe) colony formation by tumor necrosis factor alpha (TNFc~). 
Results are expressed as median of eight cultures for each group. 
CFUe and BFUe colony formation in cultures incubated without 





EPO 0,26 U/ml 
--+- o,5 
- -~ 1 
2 D 
i i i 
0 50 100 200 400 
TNF (U/ml) 
TNFe are defined as 100%. A CFUe colony formation in a aemia 
of chronic disease (ACD) patients (group 1); B CFUe colony forma- 
tion ion control patients (group 2); C BFUe colony formation n 
group 1; D BFUe colony formation in group 2. Increasing concen- 
trations of TNF~ were combined with four different concentration 
of r-h-EPO: (o) 0.25 U/ml; ([) 0.5 U/ml; (,) 1 U/ml; (n) 2 U/ml 
from both groups with 2 U/ml r-h-EPO and no TNFe, we 
found a significantly higher CFUe score as compared to 
cultures incubated with 0.25 U/ml r-h-EPO. No signifi- 
cant differences between the groups (Tables 1 and 2; 
Fig. 1) were demonstrated. 
Effect ofr-h-EPO on TNFe-suppressed CFUe and BFUe 
TNFc~ suppression was corrected with the addition of 
excess r-h-EPO as shown in Tables 1 and 2 and Fig. 1. 
Regarding CFUe (in group 1), incubation with 0.25 U/ml 
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Table 2 Effect of EPO and TNFc~ on blast forming unit erythrocyte growth. Bone marrow of eight ACD patients and eight controls was 
incubated with increasing concentrations of EPO each in combination with increasing concentrations of TNFe. The median umber of 
colonies and the range is shown 
TNF U/ml EPO U/ml 
0.25 0.5 1.0 2.0 
ACD Controls ACD Controls ACD Controls ACD Controls 
0 252 163 231 * 161 265 198" 287 207" 
(45-300) (75-310) (37-287) (115 340)  (22-400) (140-342) (22-482) (130-442) 
50 181 ** 140 232" 154 264" 168 *' ** 233 * 191 *' ** 
(15-220) (52-190) (2-357) (70-257) (22-380) (65-302) (22-342) (85-292) 
100 188 *'** 122"** 197 130"** 251 *'** 149"** 237"** 173 * 
(15-264) (32-152) (17-340) (32-182) (12-360) (75-235) (32-240) (87-485) 
200 133 *'** 62"** 164' 122"** 198"** 129"** 183 *'** 142"** 
(25 220)  (20-122) (5-292) (42-157) (10-242) (50 177)  (5-256) (75-242) 
400 91 *' ** 53" ** 107"** 102"** 159"** 107"** 151 *'** 118 *' ** 
(7-137) (20-75) (17-215) (45-165) (10-292) (42 167)  (7-280) (32-200) 
* P < 0.05 (compared to basic culture where 0.25 U/ml EPO was added without change in TNFc~ concentration) 
** P < 0.05 (compared to basic culture where no TNFe was added and no change in EPO concentration) 
r-h-EPO, and 50 U/ml and 400 U/ml TNFc~ gave sup- 
pression of 28% and 49%, respectively, compared to the 
culture without TNF~. Increasing the concentration of 
r-h-EPO from 0.25 U/ml to 2 U/ml resulted in complete 
correction of inhibition when 50 U/ml TNFe was used 
and partial correction of the TNFe suppression to 28% 
when 400 U/ml TNFc~ was added to the cultures. Similar 
results were obtained in group 2. 
The correction of TNFe inhibition also occurred in 
BFUe cultures. Regarding BFUe (in group 1), incubation 
with 0.25 U/ml r-h-EPO, and 50 U/ml and 400 U/ml 
TNF~ resulted in suppression of 33% and 61%, respec- 
tively, as compared to the cultures without TNFe. In- 
creasing the concentration of r-h-EPO from 0.25 U/ml to 
2U/ml  diminished the suppression to 17% (50 U/ml 
TNFe) and 55% (400 U/ml TNF~). BFUe growth was 
significantly more inhibited as compared to CFUe at sim- 
ilar TNFe concentrations. CFUe suppression was coun- 
teracted more by higher concentrations of r-h-EPO than 
was BFUe suppression. 
Discussion 
Many theories exist to explain the pathogenesis of ACD, 
including an impaired EPO production, decreased bone 
marrow sensitivity to EPO and inhibition of erythroid 
progenitors by cytokines such as TNFe. Our study 
demonstrated that TNFe indeed suppressed erythro- 
poiesis (CFUe and BFUe) in vitro and this inhibition was 
partly reversed by increased concentrations of r-h-EPO. 
The mechanism by which this effect occurs is un- 
known at the present. It could be speculated that EPO 
causes a down-regulation of TNFe receptor expression 
on BFUe and CFUe, thus reducing the response to the 
inhibitor. Alternatively, TNFc~ may down-regulate EPO 
receptor expression on BFUe and CFUe, with the CFUe 
and BFUe requiring higher r-h-EPO concentrations for 
optimum colony formation. Possible interactions of EPO 
and TNFe, as well as other cytokines uch as IFN7 [27], 
on receptor levels will be subjects of future studies. On the 
other hand, the inhibitory effects of TNFe could be en- 
hanced by a TNFe-mediated release of other cytokines in 
the cultures, such as IL-1 and IFNy, causing additional 
suppression of erythropoiesis [28]. 
We demonstrated that the CFUe colony growth inhi- 
bition by a low concentration of TNFe (50 U/ml) was 
completely restored when r-h-EPO was increased from 
0.25 U/ml to 2 U/ml. Apparently, in cultures where 
higher concentrations of TNFc~ were added, r-h-EPO was 
not able to counteract inhibition completely. Similar re- 
sults have been shown by Means [27] who showed that 
r-h-IFNT-related inhibition of CFUe colony growth is 
reversed by increased concentrations of r-h-EPO. The 
late erythroid progenitors (CFUe) are more dependent 
on EPO than earlier progenitors (BFUe), which also re- 
quire other growth factors (such as IL-3) for differentia- 
tion and proliferation. This may explain the better cor- 
rection of TNF~-inhibited CFUe growth with the addi- 
tion of r-h-EPO as compared to BFUe growth in our 
study. We did not establish any differences in CFUe and 
BFUe growth between RA patients with ACD and RA 
patients without anaemia. In this in vitro culture system 
we used much higher concentrations of TNFe and EPO 
than can be expected to be present in vivo, which might 
explain why no differences were observed between the 
two groups. 
Johnson et al. [25] have reported that, in TNFc~-treat- 
ed mice, EPO abrogates the TNFc~ suppressive effect in a 
dose-dependent manner. This observation has been sus- 
tained by observations [24] that EPO treatment prevents 
a decrease in the haematocrit during chronic administra- 
tion of TNFe [24]. In RA patients, circulating levels of 
TNF are much lower (max. 50 pg/ml) than those used in 
the above mentioned study [25] but the local concentra- 
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tion of TNFe in the bone marrow might be higher and 
thus participate in the pathogenesis of ACD in RA. 
Our in vitro data supported the hypothesis of lower 
levels of EPO [18], as well as elevated circulating TNFe 
serum levels [14], playing an important role in the devel- 
opment of ACD in patients with RA. Further efforts 
should be directed to demonstrating the relationship be- 
tween in vitro results and clinical observations. 
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